Gene Therapies: Bluebird Bio Presses US FDA To Reverse Denial Of Lyfgenia Priority Review Voucher

 
• By Sue Sutter
  
U-Turn Sign
Bluebird bio wants the FDA to reverse its decision denying the company a priority review voucher. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Geography